Black Diamond Therapeutics is an oncology medicine company focusing on the discovery and development of small molecule, MasterKey therapies. Co.'s proprietary technology platform, which it refers to as its Mutation-Allostery-Pharmacology drug discovery engine, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Co. has designed its clinical-stage product candidates, BDTX-1535 and BDTX-189, to selectively inhibit families of oncogenic mutations which occur across a range of tumor types that affect the ErbB-1 epidermal growth factor receptor. The BDTX average annual return since 2020 is shown above.
The Average Annual Return on the BDTX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BDTX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BDTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|